Clinical Trial

Nivolumab Combined With SOX Used in the Perioperative Treatment

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 9, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the pathological complete response rate (pCR) of nivolumab combined with SOX (oxaliplatin + S-1) for neoadjuvant therapy of resectable gastric and gastroesophageal junction adenocarcinoma;
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05739045
Lead Sponsor Xiangdong Cheng
Conditions Immune Suppression, Gastric Cancer
Enrollment 46 participants
Start Date 2022-11-03
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-09